{"entity":{"id":"nct06994507","kind":"trial","name":"GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer","aka":[],"tldr":"A phase 3 trial of GM1 in advanced solid tumours, run by Qilu Pharmaceutical Co., Ltd., now recruiting.","summary":"GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer is a phase 3 interventional study registered as NCT06994507 by Qilu Pharmaceutical Co., Ltd., with 352 participants planned, started 2025-08-01 and due to reach its primary completion in 2026-09. Interventions recorded: GM1 and Placebo.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06994507","url":"https://clinicaltrials.gov/study/NCT06994507"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["qilu-pharmaceutical"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06994507","phase":"3","setting":"A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Trial of GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer（Gypsophila )","sponsor":"Qilu Pharmaceutical Co., Ltd.","enrolled":352,"outcomes":[]},"route":"/trials/nct06994507/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"qilu-pharmaceutical","kind":"company","name":"Qilu Pharmaceutical","route":"/companies/qilu-pharmaceutical/"}]}}